Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 19, Art. 63 (pp. 880-893)    |    2018       
»

Mechanisms of interrelation of non-alcohol steatopepatitis and diabetes type 2 diabetes. Opportunities for target treatment
Salukhov V.V., Black M.S., Barsukov A.V., Kharitonov M.A., Bogomolov A.B.

S.M. Kirov Military Medical Academy, Saint Petersburg, Russia



Brief summary

The liver is a key link in the regulation of metabolic processes, ensuring the interconnection of disorders of lipid and carbohydrate metabolism. Traditionally, obesity and insulin resistance are considered as leading factors in the pathogenesis of non-alcoholic fatty liver disease and type 2 diabetes. It is understood that type 2 diabetes substantially determines the probability of non-alcoholic steatohepatitis. It is interesting if there is a reverse pattern. This review discusses the issue of the primacy of the development of hepatopathology and diabetes mellitus, which has practical potential. The ambiguity of the pathogenesis of this comorbid state dictates the need to study the effectiveness of treatment methods targeted for one nosology in relation to another.


Key words

insulin resistance, nonalcoholic steatohepatitis, type 2 diabetes mellitus





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. World Health Organization: Obesity and overweight fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 04 Nov 2016.


2. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome / A. Engin // Adv Exp Med Biol. - 2017. - N 960. - P. 1-17.


3. Diagnostika, lechenie, profilaktika ojireniya i associirovannih s nim zabolevanii (nacionalnie klinicheskie rekomendacii). - SPb., - 2017. - 164 s.


4. Younossi Z.M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes / Z.M. Younossi, A.B. Koenig, D. Abdelatif // Hepatology. - 2016. - Vol. 64. - P. 73-84.


5. Nonalcoholic fatty liver disease: Evolving paradigms / A. Lonardo [et al.] // World J Gastroenterol. - 2017. - Vol. 23, N 36. - P. 6571-6592.


6. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases / L.A. Adams [et al.] // Gut. - 2017. - Vol. 66. - P. 1138-53.


7. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases / N. Chalasani [at al.] // J. Hepatology. - 2018. - Vol. 67, N 1. - P. 328-357.


8. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the committee on causes of death in diabetes mellitus / J. Nakamura [at al.] // J Diabetes Invest. - 2017. - N 8. - P. 397-410.


9. Klinicheskie rekomendacii EASL-EASD-EASO po diagnostike i lecheniu nealkogolnoi jirovoi bolezni pecheni. Journal of Hepatology. - 2016. - vol. 64. P. 1388-1402.


10. Caligiuri A. Molecular Pathogenesis of NASH / A. Caligiuri, A. Gentilini, F. Marra // Int J Mol Sci. - 2016. - Vol. 17, N 9. - P. 1575.


11. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues / W. Mu [at al.] // Front Pharmacol. -2019. - Vol. 14, N 9. - P. 1566.


12. The interaction of hepatic lipid and glucose metabolism in liver diseases / L. P. Bechmann, R. A. [at al.] // Journal of Hepatology. - 2012. - Vol. 56, N 4. - P. 952-964.


13. Czech M.P. Insulin action and resistance in obesity and type 2 diabetes / M.P. Czech // Nat. Med. - 2017. - Vol. 23. - P. 804-814.


14. Samuel V.T. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases / V.T. Samuel, G.I. Shulman // Cell Metab. - 2018. - N 27. - P. 22-41.


15. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans / S. Ballestri [at al.] // Adv Ther. - 2016. - N 33. - P. 291-319.


16. Johnson A.M. The origins and drivers of insulin resistance / A.M. Johnson, J. M. Olefsky // Cell. - 2013. - N 152. - P. 673-684.


17. Haeusler R. A. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors / R.A. Haeusler // Nat. Commun. - 2014. - N 5. - P. 5190.


18. Catrysse L. Inflammation and the metabolic syndrome: the tissue-specific functions of NF-kappaB / L. Catrysse, van Loo G. // Trends Cell Biol. - 2017. - N 27. - P. 417-429.


19. Haas J.T. Pathophysiology and mechanisms of nonalcoholic fatty liver disease / J.T. Haas, S. Francque, B. Staels // Annu. Rev. Physiol. - 2016. - N 78. - P. 181-205.


20. Lallukka S. Non-alcoholic fatty liver disease and risk of type 2 diabetes / S. Lallukka,, H. Yki-Jarvinen // Best Pract. Res. Clin. Endocrinol. Metab. - 2016. - N 30. P. 385-395.


21. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome / A. Lonardo [at al.] // Dig Liver Dis. - 2015. - ? 47. N 181-190.


22. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology / G. Bower [et al.] // Obes Surg. - 2015. - Vol. 25, N 12. - P. 2280-2289.


23. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes / H. Yamazaki [et al.] // H. Diabetes Care. - 2015. - N 38. - P. 1673-1679.


24. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men / T. Fukuda T [et al.] // Eur J Gastroenterol Hepatol. - 2016. - N 28. - P. 1443-1449.


25. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study / S.K. Park [et al.] // Hepatology. - 2013. - N 57. P. 1378-1383.


26. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH / K. Shiba [et al.] // Sci Rep. - 2018. - N 8. - P. 2362.


27. The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease / J. Can [et al.] // J Gastroenterol Hepatol. - 2016. - PMCID: PMC5061986.


28. Karpen S.J. Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD? / S.J. Karpen // Gastroenterology. - 2013. - N 145. - P. 508-10.


29. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease / G. Porez et al. // J Lipid Res. - 2012. - N 53. - P. 1723-37.


30. Discovery of tropifexor (ljn452), a highlypotent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH) / D.C. Tully [et al.] // J Med Chem. - 2017. N 60. - P. 9960-9973.


31. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease / S. Mudaliar [et al.] // Gastroenterology. - 2013. - N 145. - P. 574-582.


32. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis / A.J. Sanyal [et al.] // N Engl J Med. - 2010. -N 362. - P. 1675-1685.


33. Molecular mechanism of PPAR alpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease / M. Pawlak,, P. Lefebvre, B. Staels // J. Hepatol. - 2015. - N 62. - P. 720-733.


34. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening / V. Ratziu // Gastroenterology. - 2015. - N150. - P. 1147-1159.


35. Dual PPARa/g agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models / M.R. Jain [et al.] // Liver Int. - 2018. - N 38. - P. 1084-1094.


36. Drucker D.J. Mechanisms of action and therapeutic application of glucagonlike peptide-1 / D.J. Drucker // Cell Metab. - 2018. - N 27. - P. 740-756.


37. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice / J.L. Trevaskis [et al.] // Am J Physiol Gastrointest Liver Physiol. - 2012. - N 302. - P. G762-G772.


38. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials / T. Vilsboll [et al.] // BMJ. - 2012. - N 344:d7771.


39. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study / M.J. Armstrong [et al.] // Lancet. - 2015. - [ePub Nov 19].


40. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans / B.S. Maciejewski [et al.] // Am. J. Physiol. Gastrointest. Liver Physiol. - 2013. - N 304u -P. G958-G969.


41. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets / T. Yamamoto [et al.] // Eur J Pharmacol. - 2010. - N 640. - P. 243-249.


42. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis / K. Yamaguchi [et al.] // Hepatology. - 2007. -N 45. - P. 1366-1374.


43. Yang M. MOGAT2: a new therapeutic target for metabolic syndrome / M. Yang, J.T. Nickels // Diseases. - 2015. - N 3. - P. 176-192.


44. (2015). JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity / C. Okuma [et al.] // Eur. J. Pharmacol. - 2015. - N 758. - P. 72-81.


45. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats / Y. Hayashizaki-Someya [et al] // Eur J Pharmacol. - 2015. - N 754. - P. 19-24.


46. Finck B.N. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis / B.N. Finck // Diabetes. - 2018. - Vol. 67, N 12u - P. 2485-2493.


47. Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvatealanine cycling / K.S. McCommis [et al.] // Cell Metab. - 2015. - N 22. - P. 682-694.


48. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis / K.S. McCommis [et al.] // Hepatology. - 2017. - N 65. - P. 1543-1556.





Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100